Targeting complement in IgA nephropathy

• Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

  2021 New England Journal of Medicine article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent

  407

  citations
• Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy

  2020 Kidney International Reports article Medicine Renal Diseases and Glomerulopathies Open access cited by 18 patents

  161

  citations
• The Contribution of Complement to the Pathogenesis of IgA Nephropathy: Are Complement-Targeted Therapies Moving from Rare Disorders to More Common Diseases?

  2021 Journal of Clinical Medicine article Immunology and Microbiology Complement system in diseases Open access

  50

  citations
• Arteriolar C4d in IgA Nephropathy: A Cohort Study

  2020 American Journal of Kidney Diseases article Medicine Renal Diseases and Glomerulopathies Open access

  42

  citations
• POS-132 TRIAL DESIGN: PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NARSOPLIMAB SAFETY AND EFFICACY IN IGA NEPHROPATHY (ARTEMIS-IGAN)

  2022 Kidney International Reports conference-abstract Medicine Renal Diseases and Glomerulopathies Open access

  8

  citations

5 results